List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 2499 studies with search of: "Lymphoma"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Conditions: Burkitt's Lymphoma;   Burkitt's Leukemia;   Mediastinal Neoplasms;   Lymphoblastic Lymphoma;   Large Cell Anaplastic Lymphoma
Interventions: Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone/Prednisolone;   Drug: VP16;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: G-CSF;   Drug: Rituximab;   Drug: Vincristine/Vindesine;   Procedure: Irradiation (in specific conditions)
2 Completed Combination Chemotherapy and Monoclonal Antibody Therapy Followed by Vaccine Therapy in Treating Patients With Mantle Cell Lymphoma
Conditions: Noncontiguous Stage II Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma
Interventions: Drug: autologous tumor cell vaccine;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: etoposide;   Drug: filgrastim;   Drug: keyhole limpet hemocyanin;   Drug: prednisone;   Drug: rituximab;   Drug: sargramostim;   Drug: vincristine
3 Recruiting Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Conditions: Hodgkin's Lymphoma;   Low Grade Lymphoma;   Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin's Lymphoma;   Diffuse Large Cell Lymphoma
Interventions: Drug: AMG 655;   Other: Vorinostat;   Other: Bortezomib
4 Recruiting Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Conditions: Follicular Lymphoma;   Marginal Zone B-Cell Lymphoma;   MALT Lymphoma;   Lymphoma of Mucosa-Associated Lymphoid Tissue;   Lymphoma, Small Lymphocytic;   Waldenstrom Macroglobulinemia;   Mantle-Cell Lymphoma
Intervention: Drug: lenalidomide-low dose dexamethasone plus rituximab
5 Recruiting Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Conditions: Peripheral T Cell Lymphoma, Unspecified;   Angioimmunoblastic Lymphadenopathy;   AIL Type Lymphoma;   Anaplastic Large Cell Lymphoma, ALK Negative;   Extranodal NK/T-Cell Lymphoma
Interventions: Biological: alemtuzumab;   Drug: chemotherapy
6 Recruiting First-Line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma
Interventions: Drug: Rituximab, Cyclophosphamide, Vincristine, Prednisone;   Drug: Rituximab, Cyclophosphamid, Doxorubicin, Vincristine, Prednisone
7 Withdrawn Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Conditions: AIDS-Related Lymphoma;   Adult Non-Hodgkin's Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: cisplatin;   Drug: cytarabine;   Drug: etoposide;   Drug: methylprednisolone;   Drug: rituximab;   Drug: yttrium Y 90 ibritumomab tiuxetan;   Procedure: antibody therapy;   Procedure: biological therapy;   Procedure: chemotherapy;   Procedure: monoclonal antibody therapy;   Procedure: radiation therapy;   Procedure: radioimmunotherapy;   Procedure: radioisotope therapy
8 Recruiting Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
Conditions: Peripheral T-Cell Lymphomas;   Adult T-Cell Leukemia;   Adult T-Cell Lymphoma;   Peripheral T-Cell Lymphoma Unspecified;   Angioimmunoblastic T-Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   T/Null Cell Systemic Type;   Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease
Intervention: Drug: Lenalidomide
9 Not yet recruiting Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Follicular Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Mantle Cell Lymphoma;   Prolymphocytic Leukemia;   Large Cell Lymphoma
Intervention: Biological: CART-19
10 Active, not recruiting Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Conditions: Burkitt Lymphoma;   Non-Hodgkins Lymphoma;   Atypical Burkitt Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Leucovorin;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Mesna
11 Completed Phase II Safety and Efficacy Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies
Conditions: Follicular Lymphoma;   Diffuse Large Cell Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: AT-101
12 Withdrawn Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
13 Recruiting A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma
Interventions: Drug: SyB L-0501;   Drug: Rituximab
14 Completed VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Lymphoma
Intervention: Drug: VELCADE and rituximab
15 Recruiting Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas
Conditions: Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Diffuse Large B-Cell Lymphoma;   T-Cell Lymphomas
Intervention: Drug: Clofarabine
16 Recruiting A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation
Conditions: Lymphoma, Large Cell, Diffuse;   Lymphoma, Mixed Cell, Diffuse;   Primary Mediastinal Large B-Cell Lymphoma;   Transformed Follicular Lymphoma;   Relapsed
Intervention: Drug: CT-011
17 Recruiting A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Diffuse Large Cell Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab Therapeutic Regimen
18 Recruiting Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0604)
Conditions: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Myeloid, Acute;   Burkitt Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse
Intervention: Biological: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation
19 Recruiting Evaluating the Safety and Effectiveness of a Bone Marrow Transplant From Partially Matched Donors and Using Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0603)
Conditions: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Myeloid, Acute;   Burkitt Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse
Intervention: Biological: Haploidentical Bone Marrow Transplantation
20 Active, not recruiting Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
Conditions: B Cell Lymphoma;   Follicular Lymphoma;   Lymphoma
Interventions: Drug: Id-KLH Vaccine;   Drug: GM-CSF

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services